CN114755334A - Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues - Google Patents
Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues Download PDFInfo
- Publication number
- CN114755334A CN114755334A CN202210380721.4A CN202210380721A CN114755334A CN 114755334 A CN114755334 A CN 114755334A CN 202210380721 A CN202210380721 A CN 202210380721A CN 114755334 A CN114755334 A CN 114755334A
- Authority
- CN
- China
- Prior art keywords
- bacitracin
- percent
- solution
- pure acetonitrile
- chromatographically pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 title claims abstract description 109
- 108010001478 Bacitracin Proteins 0.000 title claims abstract description 101
- 229960003071 bacitracin Drugs 0.000 title claims abstract description 101
- 229930184125 bacitracin Natural products 0.000 title claims abstract description 101
- 238000000034 method Methods 0.000 title claims abstract description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 96
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019253 formic acid Nutrition 0.000 claims abstract description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract 12
- 238000004458 analytical method Methods 0.000 claims description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 44
- 239000000523 sample Substances 0.000 description 25
- 238000001514 detection method Methods 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 14
- 239000011550 stock solution Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 239000012086 standard solution Substances 0.000 description 12
- 235000015277 pork Nutrition 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000012224 working solution Substances 0.000 description 8
- 238000004445 quantitative analysis Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 238000004451 qualitative analysis Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000007865 diluting Methods 0.000 description 5
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 description 5
- CFNHVUGPXZUTRR-UHFFFAOYSA-N n'-propylethane-1,2-diamine Chemical compound CCCNCCN CFNHVUGPXZUTRR-UHFFFAOYSA-N 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010016899 bacitracin A Proteins 0.000 description 3
- 108010016893 bacitracin B Proteins 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- -1 octadecyl silica gel Chemical compound 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a method for simultaneously determining bacitracin B2 and B3 contents in pig tissues, which is determined by a liquid chromatography tandem mass spectrometry method, wherein the chromatographic conditions are as follows: the mobile phase is chromatographic pure acetonitrile and 0.1 percent formic acid solution; the proportion of the mobile phase is as follows: the mixture is 20 percent of chromatographically pure acetonitrile at 0 min-0.2 min, the mixture is changed from 20 percent of chromatographically pure acetonitrile to 30 percent of chromatographically pure acetonitrile at 0.2 min-6.0 min, the mixture is changed from 30 percent of chromatographically pure acetonitrile to 80 percent of chromatographically pure acetonitrile at 6.0 min-6.1 min, the mixture is 80 percent of chromatographically pure acetonitrile at 6.1 min-7.0 min, the mixture is changed from 80 percent of chromatographically pure acetonitrile to 20 percent of chromatographically pure acetonitrile at 7.0 min-7.1 min, and the mixture is 20 percent of chromatographically pure acetonitrile at 7.1 min-9.0 min; flow rate of mobile phase: 0.300 mL/min; sample introduction amount: 10.0. mu.L.
Description
Technical Field
The invention relates to the technical field of bacitracin detection, in particular to a method capable of simultaneously determining bacitracin B2 and B3 contents in pig tissues.
Background
Bacitracin (bacitracin), an important polypeptide antibiotic, is mainly produced by bacillus licheniformis and bacillus subtilis, and the like, can interfere the synthesis of cell walls by inhibiting dephosphorylation of lipid carriers, is effective on staphylococcus, streptococcus, and the like, and is widely applied to the field of livestock breeding. Bacitracin is a multicomponent compound containing various components such as A, B, C, D, E. Currently, commercial bacitracin preparations have bacitracin a as the main active ingredient followed by bacitracin B, which contains B1, B2, B3, etc.
Aiming at the drug residue risk generated by the use of bacitracin, a series of Maximum Residual Limit (MRL) of bacitracin is established at home and abroad for monitoring, for example, national standard GB31650-2019 stipulates that the MRL of bacitracin in edible tissues of cattle, pigs and poultry is 500 microgram/kg, wherein the stipulated bacitracin residue markers are three components of bacitracin A, B, C, but currently, the existing national standard only measures bacitracin A, or partial literature measures bacitracin B, and currently, no residue analysis method respectively accurately quantifies bacitracin B2 and B3 in the bacitracin residue markers, and since bacitracin B2 and B3 have certain toxicological differences, the quantitative analysis of the bacitracin residue markers is more favorable for scientific evaluation of the bacitracin residue risk. Therefore, it is necessary to establish an analytical method capable of simultaneously and separately determining the residual content of bacitracin B2 and B3 in the porcine tissue.
Therefore, how to provide a method for determining bacitracin B2 and B3 content in pig tissues is a problem to be solved urgently by the technical personnel in the field.
Disclosure of Invention
In view of this, the invention provides a method capable of simultaneously determining bacitracin B2 and B3 content in pig tissue, which is beneficial to comprehensively evaluating bacitracin B2 and B3 content in pig tissue.
In order to achieve the purpose, the invention adopts the following technical scheme:
a method for simultaneously determining bacitracin B2 and B3 content in pig tissue comprises analyzing extracted bacitracin B2 and B3 by liquid chromatography tandem mass spectrometry, wherein the chromatographic conditions are as follows: the mobile phase is chromatographic pure acetonitrile and 0.1 percent formic acid solution; the proportion of the mobile phase is as follows: the chromatographic pure acetonitrile content is 20% at 0 min-0.2 min, is changed from 20% to 30% at 0.2 min-6.0 min, is changed from 30% to 80% at 6.0 min-6.1 min, is 80% at 6.1 min-7.0 min, is changed from 80% to 20% at 7.0 min-7.1 min, is 20% at 7.1 min-9.0 min; flow rate of mobile phase: 0.300 mL/min; sample injection amount: 10.0. mu.L.
The advantage of this elution condition is that bacitracin B2, B3 can be separated in a short analysis time with good separation, B2 and B3 are the same detection ion pair, so good separation is a prerequisite for accurate quantification thereof.
As a preferable embodiment of the above-mentioned means, the column is a C18 column, and the column temperature is 35 ℃.
As a preferable embodiment of the above-mentioned technical means, the mass spectrometry conditions in the analysis are: adopting an electrospray ion source positive source mode, wherein the voltage is 1.5KV, the desolventizing air flow rate is 800L/h, and the atomizing air temperature is 600 ℃; the airflow speed of the taper holes is 20L/h; the ion source temperature is 150 ℃; the ion scanning mode is a multiple reaction monitoring mode; the detected ion pairs are 705/199.3 and 705/110.2.
As a preferable technical scheme of the technical scheme, the method for extracting bacitracin B2 and B3 content in pig tissues comprises the following steps:
1) weighing a pig tissue sample, adding an extraction solvent, homogenizing at a high speed of 10000r/min, dispersing and extracting for 1min, centrifuging at 9500r/min for 2min, layering to obtain a supernatant A, repeatedly extracting the residual residues for 1 time according to the steps to obtain a supernatant B, and combining the two supernatants to obtain a solution C; the extraction solvent is 1% formic acid methanol, the function is to extract the residual bacitracin B2 and B3 in the sample, and the step has better extraction efficiency so as to ensure that the whole pretreatment method meets the requirement of residual analysis (namely the final recovery rate meets 70% -110%).
2) Adding n-hexane into the solution C obtained in the step 1), shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D; the n-hexane mainly has the functions of removing fat, removing lipid impurities in a sample and reducing the adverse effect of the n-hexane on subsequent detection. The step is primary purification, and removes a part of impurities to reduce impurity interference.
3) Uniformly mixing the solution D obtained in the step 2) with PSA and C18, shaking and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E; the step is a second step of purification, impurities with high acidity and polarity are removed, impurity interference is further reduced, matrix effect is reduced, and sensitivity is improved.
4) And (4) filtering the solution E obtained in the step 3) through a 0.22-micron filter membrane to obtain bacitracin B2 and B3 to be detected. This step can filter out the bigger particle impurity, prevents to get into detecting system, damages the instrument.
As a preferable technical scheme of the technical scheme, in the step 1), the mass-to-volume ratio of the pig tissue sample to the extraction solvent is 0.2-0.4 g/mL.
As a preferable technical scheme of the above technical scheme, in the step 2), the volume ratio of the solution C to n-hexane is 1: 1 to 2.
As a preferable embodiment of the above technical means, in the step 3), the volume-to-mass ratio of the solution D, PSA and C18 is 1ml to 50 mg.
According to the technical scheme, the total amount of bacitracin A or B is analyzed in the field of residual analysis according to published literature data, but B2 and B3 are not analyzed, the invention improves the problem, and the residual analysis literature does not realize good separation of bacitracin B2 and B3, particularly in short 9min instrument analysis time. Some foreign literatures realize separation of B2 and B3 by increasing the analysis time of an instrument (about 60 min) for analyzing the components of bacitracin, but the high efficiency is sacrificed, and large-batch sample detection is basically impossible for residual analysis, so that the method has the advantages of higher analysis efficiency, simplicity and high sensitivity on the whole, compared with the prior art, the method adopts UPLC-MSMS to simultaneously and respectively perform qualitative and quantitative analysis on bacitracin B2 and B3 in the pig tissues, and has short analysis time and high sensitivity; and the pretreatment process is simpler, the result is reliable, and the analysis efficiency is greatly improved.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the prior art descriptions will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 shows the chemical structures of bacitracin B2 (top) and B3 (bottom);
FIG. 2 is a quantitative ion chromatogram of bacitracin B2, B3;
FIG. 3 is a qualitative ion chromatogram of bacitracin B2, B3;
FIG. 4 is a graph showing the standard curve of bacitracin B2 in example 1;
FIG. 5 is a graph showing the standard curve of bacitracin B3 in example 1;
FIG. 6 is a qualitative ion chromatogram of bacitracin B2, B3 in comparative example 1.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
The raw materials, equipment, etc. used in all examples are known products and can be obtained by purchasing commercially available products, mainly as follows:
UPLC-MS/MS (Waters Acquity UPLC-XEVO TQ-S Micro, Waters, USA); refiner (T25, IKA, germany); high speed centrifuge (3K15, Sigma, germany); vortex mixers (GENIUS3, IKA, germany); electronic balance (Quintix124, Mettler Toledo, switzerland); a one-tenth-ten-thousandth electronic balance (XPE205, Mettler Toledo, switzerland);
acetonitrile (chromatographically pure, Merk, germany); methanol (chromatographically pure, Merk, germany); formic acid (chromatographically pure, Sigma, germany); sodium chloride (analytical grade, chemical reagents of national drug group, ltd); N-Propylethylenediamine (PSA) and octadecylsilane bonded silica (C18) (tianjin bannajie technologies ltd); pure water (Wahaha group, Inc.); bacitracin B2 standard (92.80% pure, TOKU-E, Japan) and bacitracin B3 standard (99.72% pure, TOKU-E, Japan).
In order to measure the accuracy and precision of the analysis method of the present invention, an experiment was conducted by using an addition recovery method in which bacitracin B2 and B3 mixed standard solutions were added to blank samples at concentrations of 0.01mg/kg, 0.1mg/kg and 1mg/kg, respectively, and each concentration was repeated 5 times. The specific implementation is as follows:
example 1:
(1) pretreatment method
a. Accurately weighing 2.00g of homogenized pork sample, adding 10mL of extraction solvent (1% formic acid methanol), homogenizing at 10000r/min at high speed, dispersing and extracting for 1min, centrifuging at 9500r/min for 2min, layering to obtain supernatant A, and repeatedly extracting the residual residue for 1 time according to the steps to obtain supernatant B. Mixing the two supernatants to obtain solution C;
b. adding 10mL of n-hexane into the solution C obtained in the step a, shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D;
c. taking 2mL of the solution D obtained in the step b, 100mg of N-propyl ethylenediamine (PSA) and 100mg of octadecyl bonded silica gel (C)18) Uniformly mixing, vibrating and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E;
d. and (c) taking 1.0mL of the solution E obtained in the step (c), and filtering the solution E through a 0.22-micron filter membrane to obtain a sample to be detected.
(2) Standard solution preparation
a. Preparation of a standard stock solution: weighing 10.78mg bacitracin B2 standard substance with the purity of 92.80%, and fixing the volume to 10mL by using acetonitrile to obtain bacitracin B2 standard stock solution with the concentration of 1000 mg/L; additionally weighing 10.03mg of bacitracin B3 standard substance with the purity of 99.72%, and diluting to 10mL with acetonitrile to obtain a standard stock solution of bacitracin B3 with the concentration of 997 mg/L; 1mL of the bacitracin B2 and bacitracin B3 standard stock solutions were accurately pipetted, and the volume of each stock solution was adjusted to 10mL with acetonitrile to obtain a 100mg/L mixed standard stock solution of bacitracin B2 and bacitracin B3.
b. Preparing a matrix standard working solution: accurately transferring the bacitracin B2 and bacitracin B3 mixed standard stock solution, diluting with a pig tissue blank sample constant volume solution step by step to obtain a series of matrix standard working solutions with the concentrations of 0.0005mg/L, 0.001mg/L, 0.01mg/L, 0.1mg/L and 0.2mg/L, and waiting for UPLC-MSMS detection.
(3) Detection conditions
Liquid phase conditions: the column was Waters acquitylbeh C18 (2.1X 100mm,1.7 μm); the temperature of the chromatographic column is 35 ℃; the sample injection amount is 10.0 mu L; the mobile phase is chromatographic pure acetonitrile (A) and 0.1 percent formic acid solution (B), and gradient elution is adopted (shown in a table 1); the flow rate of the mobile phase was 0.30 mL/min.
TABLE 1 liquid phase gradient elution conditions
Mass spectrum conditions: the ion source is an electrospray ion source positive source mode (ESI)+) (ii) a The capillary voltage is 1.5 KV; the desolventizing air flow rate is 800 ℃; the temperature of atomizing gas is 600 ℃; the air flow rate of the taper hole is 20L/h; the ion source temperature is 150 ℃; the ion scan mode is a multiple reaction monitoring mode (MRM) as shown in table 2.
TABLE 2 multiple reaction monitoring conditions
(4) Qualitative and quantitative analysis
The results of sample injection detection of the series of matrix standard working solutions show that the linear relation between the sample injection concentration and the peak area is good, and the method can be used for accurate quantification of bacitracin B2 and B3. The linear regression equation and the correlation coefficient r are shown in table 3.
When the addition concentration range of bacitracin B2 and B3 in pork is 0.01-1 mg/kg, the result shows that (table 4), the average recovery rate of bacitracin B2 and B3 is 81.9-93.9%, and the accuracy is good; the relative standard deviation is 1.8-4.1%, which indicates that the method has good precision; the method meets the requirement of residue analysis.
TABLE 3 Linear relationship between bacitracin B2 and B3 standard solutions of pork matrix
| Analysis of Components | Linear regression equation | Coefficient of correlation r |
| Bacitracin B2 | y＝3027897.0x+1422.2 | 0.9999 |
| Bacitracin B3 | y＝2202175.1x+1211.5 | 0.9999 |
Table 4 accuracy and precision of the pork add recovery test
Example 2:
(1) pretreatment method
a. Accurately weighing 2.00g of homogenized pork liver sample, adding 10mL of extraction solvent (1% formic acid methanol), homogenizing at 10000r/min at high speed, dispersing and extracting for 1min, centrifuging at 9500r/min for 2min, layering to obtain supernatant A, and repeatedly extracting the residual residue for 1 time according to the steps to obtain supernatant B. Mixing the two supernatants to obtain solution C;
b. adding 10mL of n-hexane into the solution C obtained in the step a, shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D;
c. taking 2mL of the solution D obtained in the step b, 100mg of N-Propylethylenediamine (PSA) and 100mg of octadecyl silica gel (C)18) Uniformly mixing, vibrating and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E;
d. and (c) taking 1.0mL of the solution E obtained in the step (c), and filtering the solution E through a 0.22-micron filter membrane to obtain a sample to be detected.
(2) Standard solution preparation
The same as in example 1.
(3) Detection conditions
The same as in example 1.
(4) Qualitative and quantitative analysis
The results of sample injection detection of the series of matrix standard working solutions show that the linear relation between the sample injection concentration and the peak area is good, and the method can be used for accurate quantification of bacitracin B2 and B3. The linear regression equation and the correlation coefficient r are shown in table 5.
When the adding concentration range of bacitracin B2 and B3 in the pig liver is 0.01-1 mg/kg, the result shows that (table 6), the average recovery rate of bacitracin B2 and B3 is 78.9-92.7%, and the accuracy is good; the relative standard deviation is 1.9-4.2%, which shows that the method has good precision; the method meets the requirement of residue analysis.
TABLE 5 Linear relationship between bacitracin B2 and B3 porcine liver stroma standard solutions
| Analytical Components | Linear regression equation | Coefficient of correlation r |
| Bacitracin B2 | y＝3344757.0x+2287.9 | 0.9999 |
| Bacitracin B3 | y＝2160775.6x+611.7 | 1.0000 |
TABLE 6 accuracy and precision of the additive recovery test in pork liver
Example 3:
(1) pretreatment method
a. Accurately weighing 2.00g of homogenized pig kidney sample, adding 10mL of extraction solvent (1% formic acid methanol), homogenizing at 10000r/min at high speed, dispersing and extracting for 1min, centrifuging at 9500r/min for 2min, layering to obtain supernatant A, and repeatedly extracting the residual residue for 1 time according to the steps to obtain supernatant B. Mixing the two supernatants to obtain solution C;
b. adding 10mL of n-hexane into the solution C obtained in the step a, shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D;
c. 2mL of the solution D obtained in step b were taken and mixed with 100mg of N-Propylethylenediamine (PSA) and 100mg of octadecyl silica gel (C)18) Uniformly mixing, vibrating and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E;
d. and (c) taking 1.0mL of the solution E obtained in the step (c), and filtering the solution E through a 0.22-micron filter membrane to obtain a sample to be detected.
(2) Standard solution preparation
The same as in example 1.
(3) Detection conditions
The same as in example 1.
(4) Qualitative and quantitative analysis
The results of sample injection detection of the series of matrix standard working solutions show that the linear relation between the sample injection concentration and the peak area is good, and the method can be used for accurate quantification of bacitracin B2 and B3. The linear regression equation and the correlation coefficient r are shown in table 7.
When the adding concentration range of bacitracin B2 and B3 in the pig tissue is 0.01-1 mg/kg, the result shows (Table 8) that the average recovery rate of bacitracin B2 and B3 is 84.0% -94.3%, which shows that the accuracy is good; the relative standard deviation is 2.2-6.5%, which shows that the method has good precision; the method meets the requirement of residue analysis.
TABLE 7 Linear relationship of bacitracin B2, B3 porcine kidney matrix standard solutions
| Analysis of Components | Linear regression equation | Coefficient of correlation r |
| Bacitracin B2 | y＝3193026.1x+970.5 | 0.9999 |
| Bacitracin B3 | y＝2133412.7x+101.2 | 1.0000 |
TABLE 8 accuracy and precision of the addition recovery test in porcine kidney
The chemical structural formulas of bacitracin B2 and B3 extracted in example 1 are shown in FIG. 1, the quantitative and qualitative ion pairs thereof are shown in FIG. 2 and FIG. 3, respectively, the standard curve of bacitracin B2 is shown in FIG. 4, and the standard curve of bacitracin B3 in example is shown in FIG. 5.
Comparative example 1 (existing elution conditions)
(1) Standard solution preparation
a. Preparation of a standard stock solution: weighing 10.78mg bacitracin B2 standard substance with purity of 92.80%, and diluting to 10mL with acetonitrile to obtain bacitracin B2 standard stock solution with concentration of 1000 mg/L; weighing 10.03mg bacitracin B3 standard substance with purity of 99.72%, and diluting to 10mL with acetonitrile to obtain standard stock solution of bacitracin B3 with concentration of 997 mg/L; 1mL of the bacitracin B2 and bacitracin B3 standard stock solutions were accurately pipetted, and the volume of each stock solution was adjusted to 10mL with acetonitrile to obtain a 100mg/L mixed standard stock solution of bacitracin B2 and bacitracin B3.
b. Preparing a matrix standard working solution: accurately transferring the mixed standard stock solution of bacitracin B2 and bacitracin B3, diluting with a pig tissue blank sample constant volume solution step by step to obtain a series of matrix standard working solutions with the concentrations of 0.0005mg/L, 0.001mg/L, 0.01mg/L, 0.1mg/L and 0.2mg/L, and waiting for UPLC-MSMS detection.
(2) Detection conditions
Liquid phase conditions: the column was Waters Acquity BEH C18 (2.1X 100mm,1.7 μm); the temperature of the chromatographic column is 35 ℃; the sample injection amount is 10.0 mu L; the mobile phase was chromatographically pure acetonitrile (a) and 0.1% formic acid solution (B), with gradient elution (as shown in table 9); the flow rate of the mobile phase was 0.30 mL/min.
TABLE 9 liquid phase gradient elution conditions
| Time/min | A proportion/%) | Proportion of B/%) |
| 0.00 | 20.0 | 80.0 |
| 0.50 | 20.0 | 80.0 |
| 1.00 | 80.0 | 20.0 |
| 6.00 | 80.0 | 20.0 |
| 6.50 | 20.0 | 80.0 |
| 9.00 | 20.0 | 80.0 |
Mass spectrum conditions: the ion source is an electrospray ion source positive source mode (ESI)+) (ii) a The capillary voltage is 1.5 KV; the desolventizing airflow rate is 800 ℃; the temperature of atomizing gas is 600 ℃; the air flow rate of the taper hole is 20L/h; the ion source temperature is 150 ℃; the ion scan mode is a multiple reaction monitoring mode (MRM) as shown in table 10.
TABLE 10 multiple reaction monitoring conditions
Comparative example 2:
(1) pretreatment method
a. Accurately weighing 2.00g of homogenized pork sample, adding 2mL of extraction solvent (1% formic acid methanol), homogenizing at a high speed of 5000r/min for dispersion and extraction for 1min, centrifuging at 9500r/min for 2min, layering to obtain supernatant A, and repeatedly extracting the residual residue for 1 time according to the steps to obtain supernatant B. Mixing the two supernatants to obtain solution C;
b. adding 10mL of n-hexane into the solution C obtained in the step a, shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D;
c. taking 1mL of the solution D obtained in the step b, 100mg of N-propyl ethylenediamine (PSA) and 100mg of octadecyl bonded silica gel (C)18) Uniformly mixing, vibrating and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E;
d. and (c) taking 1.0mL of the solution E obtained in the step (c), and filtering the solution E through a 0.22-micron filter membrane to obtain a sample to be detected.
(2) Standard solution preparation
As in comparative example 1.
(3) Detection conditions
Liquid phase conditions: the column was Waters acquitylbeh C18 (2.1X 100mm,1.7 μm); the column temperature of the chromatographic column is 35 ℃; the sample injection amount is 10.0 mu L; the mobile phase was chromatographically pure acetonitrile (a) and 0.1% formic acid solution (B), with gradient elution (as shown in table 11); the flow rate of the mobile phase was 0.30 mL/min.
TABLE 11 liquid phase gradient elution conditions
| Time/min | A proportion/%) | Proportion of B/%) |
| 0.00 | 20.0 | 80.0 |
| 0.20 | 20.0 | 80.0 |
| 6.00 | 30.0 | 70.0 |
| 6.10 | 80.0 | 20.0 |
| 7.00 | 80.0 | 20.0 |
| 7.10 | 20.0 | 80.0 |
| 9.00 | 20.0 | 80.0 |
Mass spectrum conditions: as in comparative example 1.
(4) Qualitative and quantitative analysis
The sample injection detection of the series of matrix standard working solutions shows that the linear relation between the sample injection concentration and the peak area is good within the concentration range of 0.001-0.2 mg/L. The linear regression equation and the correlation coefficient r are shown in table 12.
Bacitracin B2, B3 mixed standard solutions were added to the raw pork for additive recovery tests, which were repeated 2 times per concentration. When the addition concentration is in the range of 0.01-1 mg/kg, the results show (Table 13) that the average recovery rates of bacitracin B2 and B3 are 36.8-57.5%, and the relative standard deviation is 1.4-12.1%.
TABLE 12 bacitracin B2, B3 pork matrix standard solution linearity relationship
| Analytical Components | Linear regression equation | Coefficient of correlation r |
| Bacitracin B2 | y＝1,522,760.4x+2,423.1 | 0.9990 |
| Bacitracin B3 | y＝1,033,330.5x+3,037.3 | 0.9963 |
TABLE 13 accuracy and precision of pork add recovery test
Comparative example 1 a qualitative and quantitative ion chromatogram is shown in fig. 6.
The results of the experiment were analyzed as follows:
(1) as can be seen from comparative example 1 and FIG. 6, bacitracin B2 and B3 could not be separated effectively under the general instrumental detection conditions, and thus could not be analyzed qualitatively and quantitatively accurately.
(2) As can be seen from comparative example 2, unlike the conditions of the method of the present invention, the lowest point of the linear range of bacitracin B2, B3 became high due to the more significant matrix effect, etc., indicating that the detection sensitivity became poor and the recovery rate of addition did not satisfy the requirement of the residual analysis.
(3) As can be seen from FIGS. 2 and 3, the background of the chromatogram is clean, the interference of impurities is less, and bacitracin B2 and B3 can be well separated under the chromatographic conditions of the method, so that the qualitative and quantitative analysis of the bacitracin B2 and the bacitracin B3 are more accurate. While the sensitivity is relatively high.
(4) Compared with the prior relevant published documents, the pretreatment process of the method is greatly simplified, the SPE purification process is reduced, the impurity interference degree is small, and the time cost is saved by more than 60 percent on the whole.
(5) As can be seen from tables 3, 5 and 7 in combination with FIGS. 3 and 4, the linear relationship between the injection concentration and the response value of different porcine tissue matrix standard solutions in the range of 0.0005-0.2 mg/L is good, and the correlation coefficients r are all above 0.999, which indicates that the method can be used for accurate quantification.
(6) As can be seen from tables 4, 6 and 8, when the bacitracin B2 and B3 addition concentration in different pig tissues is in the range of 0.01-1 mg/kg, the average addition recovery rate is 78.9-94.3%, and the RSD is 1.8-6.5%, which indicates that the analysis method has good accuracy and precision and meets the related requirements of residual analysis.
In conclusion, the method adopts UPLC-MSMS to detect and simultaneously and respectively determine bacitracin B2 and bacitracin B3 residues in the pig tissues, the pretreatment process is safe and efficient, the detection sensitivity of the instrument is high, the accuracy, precision and the like of the analysis method also meet the requirements of residue analysis, and a certain technical support is provided for scientific evaluation of bacitracin residues in the pig tissues.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (7)
1. A method for simultaneously determining bacitracin B2 and B3 contents in pig tissues is characterized in that extracted bacitracin B2 and B3 are analyzed by a liquid chromatography tandem mass spectrometry method, and during analysis, the chromatographic conditions are as follows: the mobile phase is chromatographic pure acetonitrile and 0.1 percent formic acid solution; the proportion of the mobile phase is as follows: the mixture is 20 percent of chromatographically pure acetonitrile at 0 min-0.2 min, the mixture is changed from 20 percent of chromatographically pure acetonitrile to 30 percent of chromatographically pure acetonitrile at 0.2 min-6.0 min, the mixture is changed from 30 percent of chromatographically pure acetonitrile to 80 percent of chromatographically pure acetonitrile at 6.0 min-6.1 min, the mixture is 80 percent of chromatographically pure acetonitrile at 6.1 min-7.0 min, the mixture is changed from 80 percent of chromatographically pure acetonitrile to 20 percent of chromatographically pure acetonitrile at 7.0 min-7.1 min, and the mixture is 20 percent of chromatographically pure acetonitrile at 7.1 min-9.0 min; flow rate of mobile phase: 0.300 mL/min; sample introduction amount: 10.0. mu.L.
2. The method for simultaneously determining bacitracin B2 and B3 in pig tissue as claimed in claim 1, wherein the chromatographic column is C18 column and the column temperature is 35 ℃.
3. The method for simultaneously determining bacitracin B2 and B3 content in pig tissue as claimed in claim 1, wherein the mass spectrometric conditions are: adopting an electrospray ion source positive source mode, wherein the voltage is 1.5KV, the desolventizing air flow rate is 800L/h, and the atomizing air temperature is 600 ℃; the air flow rate of the taper hole is 20L/h; the ion source temperature is 150 ℃; the ion scanning mode is a multiple reaction monitoring mode; the detected ion pairs are 705/199.3 and 705/110.2.
4. The method for simultaneously determining the bacitracin B2 and B3 content in pig tissue as claimed in claim 1, wherein the method for extracting the bacitracin B2 and B3 content in pig tissue comprises the following steps:
1) weighing a pig tissue sample, adding an extraction solvent, homogenizing at a high speed of 10000r/min, dispersing and extracting for 1min, centrifuging at 9500r/min for 2min, layering to obtain a supernatant A, repeatedly extracting the residual residues for 1 time according to the steps to obtain a supernatant B, and combining the two supernatants to obtain a solution C;
2) adding n-hexane into the solution C obtained in the step 1), shaking for 1min, centrifuging at 9500r/min for 2min, layering, and removing the upper layer to obtain a solution D;
3) uniformly mixing the solution D obtained in the step 2) with PSA and C18, shaking and purifying for 1min, centrifuging at 9500r/min for 2min, and layering to obtain a solution E;
4) taking the solution E obtained in the step 3), and filtering the solution E through a 0.22 mu m filter membrane to obtain bacitracin B2 and B3 to be detected.
5. The method for simultaneously determining the bacitracin B2 and B3 content in the pig tissue as claimed in claim 4, wherein in step 1), the mass-to-volume ratio of the pig tissue sample and the extraction solvent is 0.2-0.4 g/mL.
6. The method for simultaneously determining the bacitracin B2 and B3 contents in pig tissues as claimed in claim 4, wherein in the step 2), the volume ratio of the solution C to n-hexane is 1: 1 to 2.
7. The method for simultaneously determining the bacitracin B2 and B3 content in pig tissues as claimed in claim 4, wherein in step 3), the volume-to-mass ratio of the solution D, PSA and C18 is 1ml to 50 mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210380721.4A CN114755334A (en) | 2022-04-09 | 2022-04-09 | Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210380721.4A CN114755334A (en) | 2022-04-09 | 2022-04-09 | Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114755334A true CN114755334A (en) | 2022-07-15 |
Family
ID=82329190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210380721.4A Pending CN114755334A (en) | 2022-04-09 | 2022-04-09 | Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114755334A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245238B1 (en) * | 1997-04-16 | 2001-06-12 | Erik Agner | Purification of peptides and oligonucleotides by sample displacement chromatography process and apparatus |
| CN102236005A (en) * | 2011-04-18 | 2011-11-09 | 林维宣 | Method for detecting residual quantity of multiple polypeptidepolypeptide veterinary drugs in animal-derived food |
| CN109444318A (en) * | 2018-12-03 | 2019-03-08 | 上海市食品药品检验所 | A kind of efficient liquid-phase chromatography method for analysis of bacillus peptide composition |
| RU2729620C1 (en) * | 2019-12-19 | 2020-08-11 | Федеральное государственное бюджетное научное учреждение "Федеральный центр токсической, радиационной и биологической безопасности" (ФГБНУ "ФЦТРБ-ВНИВИ") | Method for simultaneous detection of a complex of antibiotics (tetracycline group, levomycetin, bacitracin) in meat and meat products using high-performance liquid chromatography |
-
2022
- 2022-04-09 CN CN202210380721.4A patent/CN114755334A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245238B1 (en) * | 1997-04-16 | 2001-06-12 | Erik Agner | Purification of peptides and oligonucleotides by sample displacement chromatography process and apparatus |
| CN102236005A (en) * | 2011-04-18 | 2011-11-09 | 林维宣 | Method for detecting residual quantity of multiple polypeptidepolypeptide veterinary drugs in animal-derived food |
| CN109444318A (en) * | 2018-12-03 | 2019-03-08 | 上海市食品药品检验所 | A kind of efficient liquid-phase chromatography method for analysis of bacillus peptide composition |
| RU2729620C1 (en) * | 2019-12-19 | 2020-08-11 | Федеральное государственное бюджетное научное учреждение "Федеральный центр токсической, радиационной и биологической безопасности" (ФГБНУ "ФЦТРБ-ВНИВИ") | Method for simultaneous detection of a complex of antibiotics (tetracycline group, levomycetin, bacitracin) in meat and meat products using high-performance liquid chromatography |
Non-Patent Citations (6)
| Title |
|---|
| ARTEMIS K. SARRI等: "Development of a novel liquid chromatography — Evaporative light scattering detection method for bacitracins and applications to quality control of pharmaceuticals", ANALYTICA CHIMICA ACTA, 31 December 2006 (2006-12-31), pages 250 - 257 * |
| CHRISTIAN OTTO RUPERT SCHEIDL等: "Simultaneous Quantification of Neomycin and Bacitracin by LC-ELSD", CHROMATOGRAPHIA, no. 69, 31 December 2009 (2009-12-31), pages 1181 - 1188 * |
| FENG QIN等: "High Performance Liquid Chromatography‑Quadrupole/Time of Flight–Tandem Mass Spectrometry for the Characterization of Components in Bacitracin", CHROMATOGRAPHIA, pages 647 - 662 * |
| VILJEM PAVLI等: "Isolation of Peptide Components of Bacitracin by Preparative HPLC and Solid Phase Extraction (SPE)", JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, pages 2381 - 2396 * |
| 张含智等: "HPLC 结合组分制备分析杆菌肽中的有关物质及有效组分含量", 中国药学杂志, vol. 53, no. 23, pages 2041 - 2046 * |
| 聂 贞等: "兔可食性组织中杆菌肽残留量HPLC － MS/MS 测定方法", 中国兽药杂志, vol. 55, no. 3, 31 March 2021 (2021-03-31), pages 38 - 48 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7157212B2 (en) | Method for detecting dihydroxyvitamin D metabolites by mass spectrometry | |
| Davis et al. | Strategies for determination of serum or plasma norepinephrine by reverse-phase liquid chromatography | |
| KR102152310B1 (en) | Multi-residue and multi-class analytical method for agricultural chemical, veterinary drug and mycotoxin in feed | |
| US20240085386A1 (en) | Detection and quantitation of guanidinoacetate, creatine, and creatinine by mass spectrometry | |
| CN102753964A (en) | Mass spectrometric determination of non-derivatized, non-metabolized vitamin d | |
| US11624737B2 (en) | Methods for detecting lacosamide by mass spectrometry | |
| CN110780009A (en) | Method for simultaneously detecting 7 amide pesticide residues in fruits and vegetables by ultra-high performance liquid chromatography-tandem mass spectrometry | |
| CN112014509A (en) | Method for synchronously determining angiotensin I and aldosterone in sample | |
| US20110306144A1 (en) | Mass spectrometric determination of derivatized methylmalonic acid | |
| CN108445099B (en) | Method for measuring 12 local anesthetics in cosmetics | |
| CN114755334A (en) | Method for simultaneously determining bacitracin B2 and B3 contents in pig tissues | |
| Jiafeng et al. | Multiresidue determination of 19 anabolic steroids in animal oil using enhanced matrix removal lipid cleanup and ultrahigh performance liquid chromatography-tandem mass spectrometry | |
| CN113960236B (en) | Method for determining skatole and dimethyl isoborneol in fish body based on rapid pretreatment technology | |
| CN112285243B (en) | Treatment method for detecting drug residues in animal tissue sample, confirmation detection method and application thereof | |
| CN115980211A (en) | Kit and method for quantitatively detecting 25-hydroxyvitamin D and application thereof | |
| CN113655147A (en) | Method for detecting microcystin in water | |
| Hartl et al. | Rapid determination of fumonisin FB1 in corn products by high-performance liquid chromatography-electrospray mass spectrometry | |
| CN113624888B (en) | Detection method of indoleacetic acid and indolopropionic acid in serum and feces | |
| CA3094088A1 (en) | Mass spectrometric determination of testosterone in multiplexed patient samples | |
| CN116626145B (en) | Quantitative detection method of methionine iminosulfone based on multi-reaction monitoring | |
| CN113640401A (en) | Method for detecting aristolochic acid in soil | |
| CN115792010A (en) | Method for rapidly determining residual quantity of alanine in animal food based on one-step solid phase extraction | |
| CN115888187A (en) | Isolation determination of Ethanesulfonic acid Nidanib starting Material SM 2 And method of impurity thereof | |
| CN116026969A (en) | Method for splitting and measuring chlorantraniliprole and methyl chlorantraniliprole isomer by reversed-phase liquid chromatography tandem mass spectrometry | |
| CN115219636A (en) | Method for simultaneously measuring 5 mycotoxins in aquatic product at high flux |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |